Loading
Immunotherapy and Immune Responses / Cancer Research and Treatments · Journal article
Frontiers in Immunology · August 17, 2026
A consensus or society position rather than new primary data.
This narrative review examines the immunological basis and early clinical evidence for combining immune checkpoint inhibitors with radiotherapy in triple-negative breast cancer. The authors acknowledge that current evidence remains preliminary and exploratory, with several small studies demonstrating potential but no definitive clinical trial results reported; they emphasize that maximizing efficacy while controlling toxicity remains unresolved.
Narrative review article. Patients with triple-negative breast cancer, with emphasis on advanced disease.
ICI monotherapy has demonstrated limited efficacy in advanced TNBC Radiotherapy remodels the tumor immune microenvironment in addition to direct tumoricidal effects Current research on ICI-RT combination in TNBC remains in early exploratory stage
Several small studies have demonstrated potential of combination strategy, but maximizing efficacy while controlling toxicity remains a key challenge
This review provides a mechanistic framework and identifies key knowledge gaps for clinicians and researchers considering ICI-RT combinations in TNBC; it does not yet support a change in standard practice, but guides future trial design and patient selection.
A narrative review synthesizing immunological mechanisms, preclinical rationale, and early clinical evidence to guide future investigation of immunotherapy–radiotherapy combinations in TNBC, without reporting original trial results.
As stated by the source record.
This review provides a mechanistic framework and identifies key knowledge gaps for clinicians and researchers considering ICI-RT combinations in TNBC; it does not yet support a change in standard practice, but guides future trial design and patient selection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with a poor prognosis; conventional treatments provide limited durable benefit, and resistance commonly develops. The introduction of immune checkpoint inhibitors (ICIs) has expanded treatment options for TNBC; however, ICI monotherapy has demonstrated limited efficacy, particularly in patients with advanced disease. Radiotherapy (RT) has long played a pivotal role in the treatment of early-stage and locally advanced breast cancer, as it not only exerts direct tumoricidal effects but also remodels the tumor immune microenvironment. In recent years, increasing attention has been directed toward the potential synergistic effects of ICIs and RT. This article reviews the immunological characteristics of TNBC, the current status of ICI-based therapy, and the underlying mechanisms of resistance. It also summarizes the biological rationale for combining RT with ICIs in the treatment of TNBC and, in light of recent advances in clinical research, explores the impact of different RT dose-fractionation regimens, treatment sequencing, and patient selection on therapeutic efficacy. Although current research remains in an early exploratory stage and several small studies have demonstrated the potential of this combination strategy, maximizing efficacy while controlling toxicity remains a key challenge for future clinical translation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.